Phase III, Open-label, Randomized, Multi-center Study of the Effects of Leukocyte Interleukin, Injection [Multikine] Plus Standard of Care (Surgery + Radiotherapy or Surgery + Concurrent Chemoradiotherapy) in Subjects with Advanced Primary Squamous Cell Carcinoma of the Oral Cavity / Soft Palate Versus Standard of Care Only
Latest Information Update: 29 Jul 2024
At a glance
- Drugs Buffy coat interleukins (Primary) ; Cisplatin; Cyclophosphamide; Indometacin; Multivitamin; Zinc
- Indications Carcinoma; Head and neck cancer; Mouth neoplasm; Oropharyngeal cancer; Squamous cell cancer; Tongue cancer
- Focus Registrational; Therapeutic Use
- Acronyms IT-MATTERS
- Sponsors CEL-SCI Corporation
- 26 Jul 2024 Results presented in a CEL-SCI Corporation Media Release.
- 18 Jun 2024 According to a CEL-SCI media release, data from this trial presented at the International Drug Discovery Science & Technology (IDDST) 20th Annual Congress in Budapest
- 18 Jun 2024 Results published in the CEL-SCI Media Release